With the increasing use of oral oncolytics, the treatment landscape has evolved in chronic lymphocytic leukemia (CLL). Dr Allan and Dr Nachar shared their perspectives on the expanding role of the clinical pharmacist in the CLL treatment setting.
Key highlights
- Clinical pharmacists are assuming greater responsibilities in the treatment of patients with CLL, including safety monitoring, adherence support, and involvement in shared decision-making
- Patient education and financial assistance support remain important functions of the clinical pharmacist and the clinical pharmacy team
- Engagement with the multidisciplinary